Assessing the chemical diversity of an hsp90 database

European Journal of Medicinal Chemistry

Volumn 45, Issue 5, 2010, Pages 2000-2009

  Audisio, Davide ^a,b   Messaoudi, Samir ^a   Ijjaali, Ismail ^b   Dubus, Elodie ^b   Petitet, François ^b   Peyrat, Jean François ^a   Brion, Jean Daniel ^a   Alami, Mouâd ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b AUREUS PHARMA   (France)

Author keywords

Chemical diversity; Chemical fragments; Heat shock protein 90; hsp90 inhibitors; Molecular descriptors

Indexed keywords

GELDANAMYCIN; HEAT SHOCK PROTEIN; ISOXAZOLE; PROTEIN INHIBITOR; PURINE; PYRAZOLE; SCAFFOLD PROTEIN;

ARTICLE; BIOLOGICAL ACTIVITY; CHEMICAL STRUCTURE; DATA BASE; FRAGMENTATION REACTION; PRINCIPAL COMPONENT ANALYSIS; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; BINDING SITES; COMPUTATIONAL BIOLOGY; DATABASES, PROTEIN; HSP90 HEAT-SHOCK PROTEINS; ISOXAZOLES; LIGANDS; MOLECULAR STRUCTURE; PRINCIPAL COMPONENT ANALYSIS; PURINES; PYRAZOLES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77949657030     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2010.01.048     Document Type: Article

References (41)

1. Wu L.X., Xu J.H., Zhang K.Z., Lin Q., Huang X.W., Wen C.X., and Chen Y.Z. Leukemia 22 (2008) 1402-1409
2. For a more detailed client protein list see: http://www.picard.ch/downloads/hsp90interactors.pdf.
3. Banerji U. Clin. Cancer Res. 15 (2009) 9-14
4. Hanahan D., and Weinberg R.A. Cell 100 (2000) 57-70
5. Kamal A., Thao L., Sensintaffar J., Zhang L., Boehm M.F., Fritz L.C., and Burrows F.J. Nature 425 (2003) 407-410
6. Messaoudi S., Peyrat J.-F., Brion J.-D., and Alami M. Anticancer Agents Med. Chem. 8 (2008) 761-782
7. Pearl L.H., and Prodromou C. Annu. Rev. Biochem. 75 (2006) 271-294
8. Marcu M.G., Schulte T.W., and Neckers L. J. Natl. Cancer Inst. 92 (2000) 242-248
9. Solit D.B., and Chiosis G. Drug Discov. Today 13 (2008) 38-43
10. Chiosis G., Rodina A., and Moulick K. Anticancer Agents Med. Chem. 6 (2006) 1-8
11. Taldone T., Gozman A., Maharaj R., and Chiosis G. Curr. Opin. Pharmacol. 8 (2008) 370-374
12. Kasibhatla S.R., Hong K., Biamonte M.A., Busch D.J., Karjian P.L., Sensintaffar J.L., Kamal A., Lough R.E., Brekken J., Lundgren K., Grecko R., Timony G.A., Ran Y., Mansfield R., Fritz L.C., Ulm E., Burrows F.J., and Boehm M.F. J. Med. Chem. 50 (2007) 2767-2778
13. Dymock B.W., Barril X., Brough P.A., Cansfield J.E., Massey A., McDonald E., Hubbard R.E., Surgenor A., Roughley S.D., Webb P., Workman P., Wright L., and Drysdale M.J. J. Med. Chem. 48 (2005) 4212-4215
14. Le Bras G., Radanyi C., Peyrat J.-F., Brion J.-D., Alami M., Marsaud V., Stella B., and Renoir J.-M. J. Med. Chem. 50 (2007) 6189-6200
15. Radanyi C., Le Bras G., Marsaud V., Messaoudi S., Peyrat J.-F., Brion J.-D., Alami M., and Renoir J.-M. Cancer Lett. 274 (2009) 88-94
16. Radanyi C., Le Bras G., Bouclier C., Messaoudi S., Peyrat J.-F., Brion J.-D., Alami M., and Renoir J.-M. Biochem. Biophys. Res. Commun. 379 (2009) 514-518
17. Audisio D., Messaoudi S., Peyrat J.-F., Brion J.-D., and Alami M. Tetrahedron Lett. 48 (2007) 6928-6932
18. Messaoudi S., Audisio D., Brion J.-D., and Alami M. Tetrahedron 63 (2007) 10202-10210
19. Sahnoun S., Messaoudi S., Peyrat J.-F., Brion J.D., and Alami M. Tetrahedron Lett. 49 (2008) 7279-7283
20. Sahnoun S., Messaoudi S., Brion J.-D., and Alami M. Org. Biomol. Chem. 7 (2009) 4271-4278
21. Oprea T.I., and Tropsha A. Drug Discov. Today: Technol. 3 (2006) 357-365
22. Ghose A.K., Herbertz T., Salvino J.M., and Mallamo J.P. Drug Discov. Today 11 (2006) 1107-1114
23. Ijjaalli I., Dubus E., Bourinet E., and Petitet F. Channels 1 (2007) 291-299
24. Knox A.J., Price T., Pawlak M., Golfis G., Flood C.T., Fayne D., Williams D.C., Meegan M.J., and Lloyd D.G. J. Med. Chem. 52 (2009) 2177-2180
25. Lauria A., Ippolito M., and Almerico A.M. Comput. Biol. Chem. 33 (2009) 386-390
26. Dobson C.M. Nature 432 (2004) 824-828
27. Lipinski C., and Hopkins A. Nature 432 (2004) 855-861
28. Stockwell B.R. Nature 432 (2004) 846-854
29. ChemAxon, Budapest, 1037, Hungary, http://www.chemaxon.com.
30. To note: thresholds were chosen to obtain well balanced datasets, containing enough structures (i.e. information) for the analysis.
31. Rowlands M.G., Newbatt Y.M., Prodromou C., Pearl L.H., Workman P., and Aherne W. Anal. Biochem. 327 (2004) 176-183
32. Aureus Pharma, Paris, 75010, France, http://www.aureus.pharma.com.
33. Sutherland J.J., Higgs R.E., Watson I., and Vieth M. J. Med. Chem. 51 (2008) 2689-2700
34. Lewell X.Q., Judd D.B., Watson S.P., and Hann M. J. Chem. Inf. Comput. Sci. 38 (1998) 511-522
35. Le Brazidec J.Y., Kamal A., Busch D., Thao L., Zhang L., Timony G., Grecko R., Trent K., Lough R., Salazar T., Khan S., Burrows F., and Boehm M.F. J. Med. Chem. 47 (2004) 3865-3873
36. Tian Z.Q., Liu Y., Zhang D., Wang Z., Dong S.D., Carreras C.W., Zhou Y., Rastelli G., Santi D.V., and Myles D.C. Bioorg. Med. Chem. 12 (2004) 5317-5329
37. Chiosis G., Aguirre J., and Nicchitta C.V. Bioorg. Med. Chem. Lett. 16 (2006) 3529-3532
38. Chiosis G., Lucas B., Huezo H., Solit D., Basso A., and Rosen N. Curr. Cancer Drug Targets 3 (2003) 371-376
39. Donnelly A., and Blagg B.S.J. Curr. Med. Chem. 15 (2008) 2702-2717
40. Barta T.E., Veal J.M., Rice J.W., Partridge J.M., Fadden R.P., Ma W., Jenks M., Geng L., Hanson G.J., Huang K.H., Barabasz A.F., Foley B.E., Otto J., and Hall S.E. Bioorg. Med. Chem. Lett. 18 (2008) 3517-3521
41. Huang K.H., Veal J.M., Fadden R.P., Rice J.W., Eaves J., Strachan J.P., Barabasz A.F., Foley B.E., Barta T.E., Ma W., Silinski M.A., Hu M., Partridge J.M., Scott A., DuBois L.G., Freed T., Steed P.M., Ommen A.J., Smith E.D., Hughes P.F., Woodward A.R., Hanson G.J., McCall W.S., Markworth C.J., Hinkley L., Jenks M., Geng L., Lewis M., Otto J., Pronk B., Verleysen K., and Hall S.E. J. Med. Chem. 52 (2009) 4288-4305